Tasosartan

Tasosartan
Systematic (IUPAC) name
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
Clinical data
Pregnancy cat. N/A
Legal status Withdrawn
Identifiers
CAS number 145733-36-4
ATC code C09CA05
PubChem CID 60919
DrugBank DB01349
ChemSpider 54890
UNII 48G92V856H Y
Chemical data
Formula C23H21N7O 
Mol. mass 411.459 g/mol
 Y(what is this?)  (verify)

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]

References

  1. ^ Atkinson AJ et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5. 
  2. ^ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm 57 (13): 1231–41. PMID 10902066. http://www.medscape.com/viewarticle/406895. 
Antihypertensives: agents acting on the renin-angiotensin system (C09)
ACE inhibitors
("-pril")
AIIRAs/
("-sartan")
Azilsartan • Candesartan • Eprosartan • Irbesartan • Losartan • Olmesartan • Tasosartan§ • Telmisartan (+HCT) • Valsartan (+HCT)
Renin inhibitors/
("-kiren")

M: VAS

anat(a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot

noco/syva/cong/lyvd/tumr, sysi/epon, injr

proc, drug(C2s+n/3/4/5/7/8/9)